id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9192 R31823 |
Aydin (Phenytoin) (Controls exposed to Lamotrigine, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
3.67 [0.05;274.53] C excluded (control group) |
1/1 2/7 | 3 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9193 R31833 |
Aydin (Phenytoin) (Controls unexposed, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 13.67 [0.19;964.02] C | 1/1 2/22 | 3 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9272 R32154 |
Bank (Phenytoin) (Mixed indications), 2017 | Admission to neonatal intensive care unit (NICU) or Special Care Nursery | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.91 [0.04;21.24] C | 0/3 6/36 | 6 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9187 R31771 |
Artama (Phenytoin) (Controls exposed to Lamotrigine, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.13 [0.01;2.20] C excluded (control group) |
0/21 24/154 | 24 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9188 R31783 |
Artama (Phenytoin) (Controls unexposed, disease free), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
0.31 [0.02;5.20] C excluded (control group) |
0/21 49,612/689,482 | 49,612 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9190 R31807 |
Artama (Phenytoin) (Controls unexposed, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: No | 0.25 [0.01;4.13] C | 0/21 152/1,708 | 152 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9219 R31989 |
Viinikainen (Phenytoin) (Controls unexposed, disease free) a, 2006 | Admission to a neonatal unit | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No | 4.20 [0.17;103.11] C | 0/2 1,822/24,778 | 1,822 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9194 R31864 |
D'Souza (Phenytoin) (Controls unexposed, disease free), 1991 | Idiopathic respiratory distress | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
9.00 [0.35;229.68] C excluded (control group) |
1/22 0/62 | 1 | 22 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9195 R31893 |
D'Souza (Phenytoin) (Controls unexposed, sick), 1991 | Idiopathic respiratory distress | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.10 [0.04;30.00] C | 1/22 0/8 | 1 | 22 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.25 [0.29;5.38] | 1,984 | 49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenytoin) (Controls unexposed, sick; 2: Phenytoin) (Mixed indications; 3: Phenytoin) (Controls unexposed, sick; 4: Phenytoin) (Controls unexposed, disease free) ; 5: Phenytoin) (Controls unexposed, sick;
Asymetry test p-value = 0.0629 (by Egger's regression)
slope=-8.4509 (3.0261); intercept=5.2656 (1.8211); t=2.8914; p=0.0629
excluded 9194, 9187, 9188, 9192